Abstract
Both inactivated and oral poliovirus vaccines have successfully eradicated poliomyelitis in the developed world. Inactivated vaccine may appear to have some advantages for the developing world, particularly with regard to interference and greater stability, but fails to address the major reservoir of faecal-orally spread virus, the gastrointestinal tract. Inactivated vaccine used to supplement oral vaccine schedules increases cost and could cause confusion in adminis tration. Interference in oral vaccine schedules could be addressed by a supplementary neonatal dose. In most of Africa, type 1 poliovirus is the dominant endemic strain and also the cause of outbreaks, and neonatal supplementation with type 1 would have particular advantages.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
